Cell Therapeutics News

Cell Therapeutics said its cancer drug pixantrone has been approved by the European Commission for treating late-stage, aggressive B-cell non-Hodgkin lymphomas that haven't responded to other therapies.

Boston Scientific's current acquisition, Cameron Health, reports that its implantable heart defibrillator was safe and effective in a trial involving 330 patients.

The iShares NASDAQ Biotechnology Index is up nearly 20 percent year-to-date. The passage of the America Invents Act will look to benefit the Biotechnology Industry going forward "by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. patent system." BIO President and CEO Jim Greenwood stated in a ... (more)

One biotech stock that is currently on its way back up is Dendreon . Dendreon is a growing player in the biotech industry with a 1.5 current ratio reported, although this number inspires less confidence than that of other biotech companies such as Jazz Pharmaceuticals , and Cell Therapeutics , with current ratios of 4.2 and 3.1, respectively.

Watson Pharmaceuticals of the US acquired privately held Actavis Group at a price of about $5.6 billion upfront, plus earn-out provisions based on 2012 results .